{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:01:09Z","timestamp":1792173669058,"version":"4.4.0"},"reference-count":99,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Two years after severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), in December 2019, the first infections were identified in Wuhan city of China. SARS-CoV-2 infection caused a global pandemic and accordingly, 5.41 million deaths worldwide. Hence, developing a safe and efficient vaccine for coronavirus disease 2019 (COVID-19) seems to be an urgent need. Attempts to produce efficient vaccines inexhaustibly are ongoing. At present time, according to the COVID-19 vaccine tracker and landscape provided by World Health Organization (WHO), there are 161 vaccine candidates in different clinical phases all over the world. In between, protein subunit vaccines are types of vaccines that contain a viral protein like spike protein or its segment as the antigen assumed to elicit humoral and cellular immunity and good protective effects. Previously, this technology of vaccine manufacturing was used in a recombinant influenza vaccine (RIV4). In the present work, we review protein subunit vaccines passing their phase 3 and 4 clinical trials, population participated in these trials, vaccines manufactures, vaccines efficiency and their side effects, and other features of these vaccines.<\/jats:p>","DOI":"10.3389\/fmicb.2022.927306","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T03:11:11Z","timestamp":1657768271000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":158,"title":["A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19"],"prefix":"10.3389","volume":"13","author":[{"given":"Mohsen","family":"Heidary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahab Hassan","family":"Kaviar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Shirani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roya","family":"Ghanavati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moloudsadat","family":"Motahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Sholeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Ghahramanpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Khoshnood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10070788","article-title":"A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development.","volume":"10","author":"Abdulla","year":"2021","journal-title":"Pathogens"},{"key":"B2","year":"2021","journal-title":"Cuban-Developed Vaccine Enters Phase III Trial."},{"key":"B3","author":"Acosta","year":"2021","journal-title":"Cuba Encouraged by Early Efficacy Results of COVID-19 Vaccine."},{"key":"B4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.37757\/MR2021.V23.N3.3","article-title":"Cuba\u2019s National Regulatory Authority & COVID-19: olga Lidia Jacobo-Casanueva MS Director. Center for State Control of Medicines and Medical Devices (CECMED).","volume":"23","author":"Aguilar-Guerra","year":"2021","journal-title":"MEDICC Rev."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2183","article-title":"Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: state of the art and future prospects.","volume":"31","author":"Arashkia","year":"2021","journal-title":"Rev. Med. Virol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2014.00365","article-title":"The dichotomy of pathogens and allergens in vaccination approaches.","volume":"5","author":"Baird","year":"2014","journal-title":"Front. Microbiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.vaccine.2016.02.033","article-title":"Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola\/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.","volume":"34","author":"Bengtsson","year":"2016","journal-title":"Vaccine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/jphp.12353","article-title":"Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?.","volume":"67","author":"Bill","year":"2015","journal-title":"J. Pharm. Pharmacol."},{"key":"B9","year":"","journal-title":"ReCOV."},{"key":"B10","year":"","journal-title":"Unnamed Inactive Vaccine - Jiangsu."},{"key":"B11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(22)00055-1","article-title":"Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.","volume":"399","author":"Bravo","year":"2022","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-00268-9","article-title":"Novavax covid vaccine protects people against variants.","volume":"590","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41422-021-00514-9","article-title":"Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines.","volume":"31","author":"Cao","year":"2021","journal-title":"Cell Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.13005\/bpj\/2214","article-title":"The Recent Updates on Approaches and Clinical Trials Status of Covid-19 Vaccines Developed Globally.","volume":"14","author":"Chaudhary","year":"2021","journal-title":"Biomed. Pharmacol. J."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccmp.2021.100004","article-title":"COVAX-19\u00ae Vaccine: completely blocks virus transmission to non-immune individuals.","volume":"1","author":"Chavda","year":"2021","journal-title":"Clin. Compl. Med. Pharmacol."},{"key":"B16","year":"2021","journal-title":"A Phase III, Randomized, Two-armed, Double-blind, Placebo controlled trial to evaluate efficacy and safety of an adjuvanted recombinant SARS-CoV-2 spike (S) protein subunit vaccine (SpikoGen<sup>\u00ae<\/sup>) produced by CinnaGen Co."},{"key":"B17","year":"2021","journal-title":"A Phase II, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)"},{"key":"B18","year":"2022","journal-title":"Safety, Reactogenicity and Immunogenicity Study of ReCOV."},{"key":"B19","year":"","journal-title":"Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2\/3 Clinical Trial for its COVID-19 Vaccine Candidate."},{"key":"B20","year":"","journal-title":"Clover\u2019s COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2\/3 SPECTRA Trial Dominated by Variants of Concern and Interest."},{"key":"B21","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3390\/covid1030051","article-title":"SARS-CoV-2 Targets and COVID-19 Vaccines.","volume":"1","author":"Currier","year":"2021","journal-title":"COVID"},{"key":"B22","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS.","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013652","article-title":"Antibody tests for identification of current and past infection with SARS-CoV-2.","volume":"6","author":"Deeks","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"B24","year":"2021","journal-title":"Info about Corbevax\/Becov2 Vaccine developed by Biological E, BCM and Dynavax."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00352-y","article-title":"Systematic review of SARS-CoV-2 vaccine candidates.","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2014a target for vaccine and therapeutic development.","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.","volume":"386","author":"Dunkle","year":"2021","journal-title":"New Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10010062","article-title":"Narrative Review of COVID-19 Vaccines.","volume":"10","author":"Eroglu","year":"2021","journal-title":"Vaccines"},{"key":"B29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1586\/erv.11.192","article-title":"Development and evaluation of AS03, an Adjuvant System containing \u03b1-tocopherol and squalene in an oil-in-water emulsion.","volume":"11","author":"Gar\u00e7on","year":"2012","journal-title":"Exp. Rev. Vaccines"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.34172\/ipp.2021.31","article-title":"Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion.","volume":"7","author":"Ghiasi","year":"2021","journal-title":"Immunopathol. Persa"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S1473-3099(21)00147-X","article-title":"Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1\u20132, dose-ranging study.","volume":"21","author":"Goepfert","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.30.399154","article-title":"A novel sars-cov-2 multitope protein\/peptide vaccine candidate is highly immunogenic and prevents lung infection in an adeno associated virus human angiotensin-converting enzyme 2 (aav hace2) mouse model.","author":"Guirakhoo","year":"2020","journal-title":"bioRxiv"},{"key":"B33","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jconrel.2021.06.036","article-title":"Nanotechnology against COVID-19: immunization, diagnostic and therapeutic studies.","volume":"336","author":"Hasanzadeh","year":"2021","journal-title":"J. Control. Release"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine.","volume":"385","author":"Heath","year":"2021","journal-title":"New Engl. J. Med."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1101\/2021.11.30.21267047","article-title":"Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study).","author":"Hernandez-Bernal","year":"2021","journal-title":"medRxiv"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/S1473-3099(20)30773-8","article-title":"What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.","volume":"21","author":"Hodgson","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1172\/JCI139569","article-title":"SARS\u2013CoV-2 infection of the placenta.","volume":"130","author":"Hosier","year":"2020","journal-title":"J. Clin. Investig."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/S2213-2600(21)00402-1","article-title":"Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.","volume":"9","author":"Hsieh","year":"2021","journal-title":"Lancet Resp. Med."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00082-3","article-title":"Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y. V2.","volume":"2","author":"Huang","year":"2021","journal-title":"Lancet Microbe"},{"key":"B40","year":"2021","journal-title":"Efficacy, Safety, and Immunogenicity of Soberana Recombinant Vaccine (Product of Finlay Institute) based on RBD Protein Subunit of Sars-Cov-2 in a 2-Dose Regimen with and without a Booster Dose: a Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial in the Iranian population of 18-80 Years."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease.","volume":"6","author":"Jacob","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B42","author":"Johnson","year":"2021","journal-title":"Large Study Finds that Vaccine Maker Novavax\u2019s Shot is About 90% Effective."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9111740","article-title":"Counting on COVID-19 vaccine: insights into the current strategies, progress and future challenges.","volume":"9","author":"Kandimalla","year":"2021","journal-title":"Biomedicines"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1590\/1678-4685-GMB-2020-0320","article-title":"SARS-CoV-2 vaccine development and how Brazil is contributing.","volume":"44","author":"Kanno","year":"2021","journal-title":"Genet. Mol. Biol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine.","volume":"383","author":"Keech","year":"2020","journal-title":"New Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2478\/folmed-2018-0007","article-title":"Bacterial Co-infections in HIV\/AIDS-positive Subjects: a Systematic Review and Meta-analysis.","volume":"60","author":"Khademi","year":"2018","journal-title":"Folia Med."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmni.2020.100770","article-title":"Diagnostic approaches and potential therapeutic options for coronavirus disease (COVID-19).","volume":"38","author":"Khan","year":"2020","journal-title":"New Microbes New Infect."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24418","article-title":"An overview on inactivated and live-attenuated SARS-CoV-2 vaccines.","volume":"36","author":"Khoshnood","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24402","article-title":"Clinical manifestations, treatment options, and comorbidities in COVID-19 relapse patients: a systematic review.","volume":"36","author":"Koupaei","year":"","journal-title":"J. Clin. Lab. Anal."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24426","article-title":"Clinical symptoms, diagnosis, treatment, and outcome of COVID-19-associated encephalitis: a systematic review of case reports and case series.","volume":"36","author":"Koupaei","year":"","journal-title":"J. Clin. Lab. Anal"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.740593","article-title":"Clinical Characteristics. Diagnosis, Treatment, and Mortality Rate of TB\/COVID-19 Coinfectetd Patients: a Systematic Review.","volume":"8","author":"Koupaei","year":"2021","journal-title":"Front. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1007\/s13346-021-01001-9","article-title":"Mucosal and transdermal vaccine delivery strategies against COVID-19.","volume":"12","author":"Kumar","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1101\/2021.10.18.21265169","article-title":"Elevated antibody titers in Abdala vaccinees evaluated by Elecsys\u00ae anti-SARS-CoV-2 S highly correlate with UMELISA SARS-CoV-2 ANTI RBD, ACE-2 binding inhibition and viral neutralization assays.","author":"Lemos-Perez","year":"2021","journal-title":"medRxiv"},{"key":"B54","doi-asserted-by":"publisher","first-page":"5940","DOI":"10.1016\/j.vaccine.2021.07.087","article-title":"Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection.","volume":"39","author":"Li","year":"2021","journal-title":"Vaccine"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-21634-1","article-title":"S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates.","volume":"12","author":"Liang","year":"2021","journal-title":"Nat. Commun."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88283-8","article-title":"CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge.","volume":"11","author":"Lien","year":"2021","journal-title":"Sci. Rep."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-09518-1","article-title":"Improvement of pharmacokinetic profile of TRAIL via trimer-tag enhances its antitumor activity in vivo.","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24403","article-title":"Neurological manifestations in patients with COVID-19: a systematic review and meta-analysis.","volume":"36","author":"Mahdizade Ari","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.31.228486","article-title":"SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses.","author":"Mandolesi","year":"2020","journal-title":"BioRxiv"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701501","article-title":"CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.","volume":"12","author":"Mart\u00ednez-Flores","year":"2021","journal-title":"Front. Immunol."},{"key":"B61","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24387","article-title":"Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: a systematic review and meta-analysis.","volume":"36","author":"Naimi","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"B62","year":"2020","journal-title":"Cuba negotiates with other countries to develop phase 3 of Soberana 02 vaccine."},{"key":"B63","author":"Pasteur","year":"2020","journal-title":"Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older."},{"key":"B64","author":"Pasteur","year":"2021","journal-title":"Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older."},{"key":"B65","first-page":"14","article-title":"Evaluation of ELISA and Brucellacapt tests for diagnosis of human Brucellosis.","volume":"5","author":"Peeridogaheh","year":"2013","journal-title":"Iran. J. Microbiol."},{"key":"B66","first-page":"24","article-title":"Six Up-and-Coming COVID-19 Vaccines: besides Pfizer\/BioNTech, Moderna, and J&J, many other biopharmas have jabs in the clinic that have shown significant protection against SARS-CoV-2.","volume":"41","author":"Philippidis","year":"2021","journal-title":"Genet. Eng. Biotechnol. News"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101612","article-title":"Can the Nasal Cavity Help Tackle COVID-19?","volume":"13","author":"Pilicheva","year":"2021","journal-title":"Pharmaceutics"},{"key":"B68","year":"2021","journal-title":"GSK\/SK Bioscience COVID-19 Vaccine to Enter Phase 3 Trial."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-10183-3","article-title":"Rapid review of COVID-19 epidemic estimation studies for Iran.","volume":"21","author":"Pourmalek","year":"2021","journal-title":"BMC Public Health"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abc8413","article-title":"The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.","volume":"5","author":"Premkumar","year":"2020","journal-title":"Sci. Immunol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/d41586-021-03470-x","article-title":"Cuba\u2019s bet on home-grown COVID vaccines is paying off.","volume":"600","author":"Reardon","year":"2021","journal-title":"Nature"},{"key":"B72","article-title":"Persistence of the immune responses and cross-neutralizing activity with Variants of Concern following two doses of adjuvanted SCB-2019 COVID-19 vaccine.","volume":"4","author":"Richmond","year":"2021","journal-title":"J. Infect. Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S0140-6736(21)00241-5","article-title":"Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.","volume":"397","author":"Richmond","year":"2021","journal-title":"Lancet"},{"key":"B74","doi-asserted-by":"publisher","first-page":"5","DOI":"10.15690\/vramn1528","article-title":"Immunogenicity and protectivity of the peptide vaccine against SARS-CoV-2.","volume":"76","author":"Ryzhikov","year":"2021","journal-title":"Ann. Russ. Acad. Med. Sci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"283","DOI":"10.15789\/2220-7619-ASB-1699","article-title":"A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the \u201cEpivaccorona\u201d vaccine for the prevention of Covid-19, in volunteers aged 18-60 years (phase I-Ii).","volume":"11","author":"Ryzhikov","year":"2021","journal-title":"Russ. J. Infect. Immun."},{"key":"B76","year":"","journal-title":"Sanofi and Gsk"},{"key":"B77","year":"","journal-title":"Phase 3 Clinical Trial for COVID-19 Recombinant Protein Vaccine Candidate."},{"key":"B78","year":"","journal-title":"Sanofi and GSK Initiate Global Phase 3 Clinical Efficacy Study of COVID-19 Vaccine Candidate."},{"key":"B79","year":"","journal-title":"Study of Adjuvanted Recombinant COVID-19 Vaccine Candidate as a Primary Series and as a Booster Dose Against COVID."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202100985","article-title":"Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: a Peptide-Based Vaccine Alternative.","volume":"8","author":"Shalash","year":"2021","journal-title":"Adv. Sci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","article-title":"Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B. 1.351 Variant.","volume":"384","author":"Shinde","year":"2021","journal-title":"New Engl. J. Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/zph.12622","article-title":"A comparison of three data mining time series models in prediction of monthly brucellosis surveillance data.","volume":"66","author":"Shirmohammadi-Khorram","year":"2019","journal-title":"Zoonoses Public Health"},{"key":"B83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19.","volume":"11","author":"Smith","year":"2020","journal-title":"Nat. Commun."},{"key":"B84","year":"2021","journal-title":"Registro P\u00fablico Cubano de Ensayos Cl\u00ednicos\u201d. Cuban Registry of Clinical Trials (in Spanish)"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030404","article-title":"COVID 19: mechanisms of vaccination and immunity.","volume":"8","author":"Speiser","year":"2020","journal-title":"Vaccines"},{"key":"B86","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.","volume":"17","author":"Tai","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"B87","year":"2021","journal-title":"COVID-19 Vaccine Razi Cov Pars Starts Third Clinical Trial Phase."},{"key":"B88","year":"2021","journal-title":"Cuba says second COVID-19 vaccine Soberana 2 boasts 91.2% efficacy. The Indian Express."},{"key":"B89","year":"2021","journal-title":"New Chinese vaccine shows 82% effectiveness against serious Covid-19 The Straits Times."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20653-8","article-title":"SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.","volume":"12","author":"Tian","year":"2021","journal-title":"Nat. Commun."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1101\/2021.10.31.21265703","article-title":"Efficacy and Safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three doses combination.","author":"Toledo-Romani","year":"2021","journal-title":"medRxiv"},{"key":"B92","year":"2021","journal-title":"Cuba Inicia Nova Fase De Testes Com Vacina Que Desenvolve Contra Covid-19 (in Portuguese)."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.08.430146","article-title":"SARS-CoV-2 RBD-Tetanus toxoid conjugate vaccine induces a strong neutralizing immunity in preclinical studies.","author":"Valdes-Balbin","year":"2021","journal-title":"bioRxiv"},{"key":"B94","author":"Verma","year":"2021","journal-title":"Reassess, Reorganize &amp; Realign Vision For Effective Inoculation: A Holistic Review Of Sars Covid-19 Vaccination Drive In India."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00298","article-title":"Subunit vaccines against emerging pathogenic human coronaviruses.","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Microbiol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","article-title":"Structural and functional basis of SARS-CoV-2 entry by using human ACE2.","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B98","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4103\/0256-4947.81543","article-title":"Epidemiological and clinical features of Brucella arthritis in 24 children.","volume":"31","author":"Zamani","year":"2011","journal-title":"Ann. Saudi Med."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00217-2","article-title":"Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants.","volume":"2","author":"Zhao","year":"2021","journal-title":"Lancet Microbe"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.927306\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T03:11:30Z","timestamp":1657768290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.927306\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":99,"alternative-id":["10.3389\/fmicb.2022.927306"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2022.927306","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"article-number":"927306"}}